Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
Quels sont les états financiers clés de Zai Lab Limited ?
Selon le dernier état financier (Form-10K), Zai Lab Limited a un total d'actifs de $0, un bénéfice net 損失 de $0
Quels sont les ratios financiers clés pour ZLAB ?
Le ratio de liquidité de Zai Lab Limited est 0, la marge nette est 0, les ventes par action sont de $0.
Comment les revenus de Zai Lab Limited sont-ils répartis par segment ou géographie ?
Zai Lab Limited の最大収益セグメントは Innovative Therapies で、最新の利益発表における収益は 3,587,394,608 です。地域別に見ると、Greater China and United States が Zai Lab Limited の主要市場であり、収益は 3,587,394,608 です。
Zai Lab Limited est-elle rentable ?
いいえ, selon les derniers états financiers, Zai Lab Limited a un bénéfice net 損失 de $0
Zai Lab Limited a-t-elle des passifs ?
いいえ, Zai Lab Limited a un passif de 0
Combien d'actions en circulation Zai Lab Limited a-t-elle ?
Zai Lab Limited a un total d'actions en circulation de 0